Last reviewed · How we verify
Pregnant women exposed to tildrakizumab
Pregnant women exposed to tildrakizumab is a Small molecule drug developed by Sun Pharmaceutical Industries Limited. It is currently in Phase 2 development.
At a glance
| Generic name | Pregnant women exposed to tildrakizumab |
|---|---|
| Sponsor | Sun Pharmaceutical Industries Limited |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Safety Study for Prospective Assessment of Pregnancy Outcomes in Patients Treated With Tildrakizumab
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pregnant women exposed to tildrakizumab CI brief — competitive landscape report
- Pregnant women exposed to tildrakizumab updates RSS · CI watch RSS
- Sun Pharmaceutical Industries Limited portfolio CI
Frequently asked questions about Pregnant women exposed to tildrakizumab
What is Pregnant women exposed to tildrakizumab?
Pregnant women exposed to tildrakizumab is a Small molecule drug developed by Sun Pharmaceutical Industries Limited.
Who makes Pregnant women exposed to tildrakizumab?
Pregnant women exposed to tildrakizumab is developed by Sun Pharmaceutical Industries Limited (see full Sun Pharmaceutical Industries Limited pipeline at /company/sun-pharmaceutical-industries-limited).
What development phase is Pregnant women exposed to tildrakizumab in?
Pregnant women exposed to tildrakizumab is in Phase 2.